ANTARES: Feasibility and Safety of the Routine Distal Transradial Approach

Sponsor
Łukasz Koziński (Other)
Overall Status
Completed
CT.gov ID
NCT05982366
Collaborator
(none)
400
1
2
6.9
57.7

Study Details

Study Description

Brief Summary

The distal transradial approach (dTRA) via the anatomical snuffbox is hypothesized to be more beneficial than the conventional transradial access (cTRA) in patients undergoing coronary procedures. This prospective single-center randomized trial was designed to investigate the safety, efficacy, and various ultrasound parameters of dTRA.

Condition or Disease Intervention/Treatment Phase
  • Other: distal radial artery acess side
  • Other: conventional radial artery acess side
N/A

Detailed Description

Transradial approach (TRA) has emerged in most countries as a default strategy in urgent and elective coronary procedures. The advantages of TRA compared to the transfemoral access encompass a reduction of mortality, complications, and cost as well as improvement of patient's comfort. The aim of the present study (ANTARES, distAl vs coNventional Transradial Access for coRonary procEdures Study) was to assess the feasibility, safety and various ultrasound parameters of dTRA in the anatomical snuffbox as the first-line strategy, in comparison with cTRA, in patients undergoing coronary angiography (CAG) and percutaneous coronary intervention (PCI). The study is a non-inferiority, randomized controlled trial. There are two arms: distal transradial access and conventional transradial approach.

400 patients were enrolled.

Study Design

Study Type:
Interventional
Actual Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, single-center, randomized trialProspective, single-center, randomized trial
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
distAl vs. coNventional Transradial Access for coRonary procEdures Study (ANTARES)
Actual Study Start Date :
Nov 1, 2022
Actual Primary Completion Date :
Feb 28, 2023
Actual Study Completion Date :
May 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Distal transradial approach

Distal transradial approach as the default strategy

Other: distal radial artery acess side
coronary procedure (coronary angiography and/or coronary angioplasty) by the distal radial artery in the anatomical snuffbox area
Other Names:
  • dTRA
  • Active Comparator: Conventional transradial approach

    Conventional transradial approach as the default strategy

    Other: conventional radial artery acess side
    coronary procedure (coronary angiography and/or coronary angioplasty) by the forearm radial artery in the anatomical snuffbox area
    Other Names:
  • cTRA
  • Outcome Measures

    Primary Outcome Measures

    1. The primary composite endpoint consisted of rate of access crossover, rate of major adverse cardiovascular events (MACE) and rate of access-related vascular complications. [up to 24 hours]

      Access crossover from unsuccessful random arterial access (if the initial access point fails) to another one. Access-related complications after the procedure measured with Doppler Ultrasound (included radial artery occlusion, significant hematoma (EASY classification grade III-V), arteriovenous fistula, pseudoaneurysm, perforation and spasm). MACE definied as myocardial infarction, stroke, urgent revascularization, all-cause death.

    Secondary Outcome Measures

    1. efficacy endpoint: rate of access crossover [during the procedure index]

      Access crossover from unsuccessful random arterial access (if the initial access point fails) to another one.

    2. safety endpoint: patients' discomfort evaluated during access performance [during the procedure]

      physical discomfort at the time of vascular access performance was assessed using a numerical scale (0/1/2/3 - respectively no/mild/moderate/severe discomfort)

    3. efficacy endpoint: duration of access performance [during the procedure index]

      (measured from the time of skin puncture with local anesthetic to the successful sheath insertion confirmed by an outflow of arterial blood)

    4. safety endpoint: access-site vascular complications [after 24 hours post procedure]

      it is composed by the rate of radial artery occlusion, significant hematoma (EASY classification grade III-V), arteriovenous fistula, pseudoaneurysm, perforation and spasm; measured with Doppler Ultrasound

    Other Outcome Measures

    1. Access-time [during procedure]

      counted from local anesthesia to successful insertion of the sheath

    2. radial artery size [before the procedure, 24 hours and 60 days after the procedure]

      parameter measured by Doppler Ultrasound at the access point

    3. radial artery velocity [before the procedure, 24 hours and 60 days after the procedure]

      parameter measured by Doppler Ultrasound at the access point

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients referred for CAG and/or PCI
    Exclusion Criteria:
    • ST-elevation myocardial infarction

    • sudden cardiac arrest

    • hemody-namic instability

    • chronic kidney disease (stages 4-5)

    • forearm artery occlusion

    • previous unsuccessful ipsilateral TRA

    • unfavorable RA diameter

    • ultrasound unavailability

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Szpital Specjalistyczny Chojnice Pomeranian Poland 89-600

    Sponsors and Collaborators

    • Łukasz Koziński

    Investigators

    • Study Chair: Łukasz Koziński, MD, Indywidualna Praltyka Lekarska Lekarz Łukasz Koziński

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Łukasz Koziński, Principal Investigator Łukasz Koziński, Indywidualna Praktyka Lekarska Lekarz Łukasz Koziński, Indywidualna Praktyka Lekarska Lekarz Łukasz Koziński
    ClinicalTrials.gov Identifier:
    NCT05982366
    Other Study ID Numbers:
    • AntaresStudy01
    First Posted:
    Aug 8, 2023
    Last Update Posted:
    Aug 8, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Łukasz Koziński, Principal Investigator Łukasz Koziński, Indywidualna Praktyka Lekarska Lekarz Łukasz Koziński, Indywidualna Praktyka Lekarska Lekarz Łukasz Koziński
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 8, 2023